
Home » ACTELION SLUMPS ON CLAZOSENTAN STUDY OUTCOME
ACTELION SLUMPS ON CLAZOSENTAN STUDY OUTCOME
Swiss pharmaceutical company Actelion Ltd Monday said a study of its brain artery drug clazosentan showed that more time is needed to determine whether the product is effective, in a major setback that sent the shares sharply lower.
Therapeutics Daily
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb
-
07Mar